Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22958995 | 0.86 | TLR7 (0.46) | TLR7TLR8ALDH1A1 | |
| SCHEMBL22959007 | 0.78 | EIF4A1 (0.37) | TLR7TLR8KCNH2 | |
| SCHEMBL22959028 | 0.78 | TLR7 (0.40) | TLR7TLR8KCNH2 | |
| SCHEMBL22958959 | 0.73 | ALDH1A1 (0.33) | HPGDDHFRTP53KCNH2ALDH1A1 | |
| SCHEMBL15502359 | 0.73 | TLR7 (0.61) | TLR7TLR8TP53CYP3A4CYP2D6 | |
| SCHEMBL22958999 | 0.71 | CYP2C9 (0.59) | TLR7TLR8KCNH2CYP3A4CYP2D6 | |
| SCHEMBL24384575 | 0.71 | TLR8 (0.64) | TLR7TLR8KCNH2CYP2D6 | |
| SCHEMBL24384574 | 0.71 | TLR7 (0.38) | TLR7TLR8DHFRKCNH2 | |
| SCHEMBL22958984 | 0.70 | KCNH2 (0.48) | TLR7TLR8DHFRKCNH2CYP3A4 | |
| SCHEMBL22958996 | 0.70 | KCNH2 (0.35) | KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278964-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2023-09-07 | — | — | US | disclosed |
| US-20210040046-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimi (IE) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040046-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | HRH4, HRH3, HNMT | TLR7 52/4885TLR8 400/4885HPGD 1674/4885 |
| US-20230278964-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | QDPR, PADI2, PEPD | TLR7 728/4885TLR8 584/4885HPGD 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.